<DOC>
	<DOCNO>NCT03079219</DOCNO>
	<brief_summary>The Olanzapine Regimen superior Standard Regimen , measure proportion patient Complete Response 120 hour follow AC chemotherapy .</brief_summary>
	<brief_title>Olanzapine Prevention Chemotherapy-Induced Nausea Vomiting Chinese Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Chinese patient , female &gt; =18 &lt; 75 year age . Patient diagnose early breast cancer . Patient na√Øve emetogenic chemotherapy moderately highly emetogenecity . Patient schedule receive first course adjuvant chemotherapy breast cancer follow : IV adriamycin 60 mg/m2 + cyclophosphamide 600 mg/m2 Patient predict life expectancy 4 month . Patient ECOG Performance Status 01 Premenopausal female patient must pregnant ( document negative urine pregnancy test ) . Patient able read , understand complete study questionnaire diary , include question require visual analog scale ( VAS ) response . Patient understand procedure agree participate study give write informed consent Patient advance breast cancer . Patient receive cisplatin chemotherapy high emetogenic potential , except cyclophosphamide doxorubicin regimen describe . Patients schedule receive concurrent radiation part chemotherapy regimen malignancy Patients experience vomit grade 23 nausea per Common Terminology Criteria Adverse Events version 4.0 ( CTCAE v 4.03 ) 24 hour Day 1 chemotherapy Patient history treatment moderately highly emetogenic chemotherapy . Patient active infection ( e.g. , pneumonia , systemic fungal infection ) uncontrolled disease ( e.g. , diabetes mellitus , hypertension ) , opinion investigator , might confound result study pose unwarranted risk . Patient history glaucoma , dementia , seizure , Parkinson 's disease , Neuroleptic Malignant Syndrome ( NMS ) , thromboembolic event . Patient currently use illicit drug , include marijuana , current evidence alcohol abuse determine investigator . Patient mentally incapacitate significant emotional psychiatric disorder , opinion investigator , precludes study entry . Patients regular alcohol drinker smoker Patient history illness , opinion investigator , might confound result study pose unwarranted risk . Patient history hypersensitivity aprepitant , ondansetron dexamethasone . Patients phenylketonuria abnormal uric acid . Any investigational drug take within 4 week prior Day 1 cycle 1 , and/or schedule receive investigational drug study ; Patient take systemic corticosteroid therapy dose ; however , topical inhale corticosteroid permit . Patient take nonregistered investigational drug within 28 day Prestudy Visit . Use , 28 day prior Treatment Day 1 , barbiturate , rifampicin rifabutin , phenytoin carbamazepine Use , 7 day prior Treatment Day 1 , terfenadine , cisapride , astemizole , clarithromycin ( azithromycin , erythromycin roxithromycin permit ) , ketoconazole itraconazole ( fluconazole permit ) , amifostine pimozide 5HT3 antagonist ( ondansetron , granisetron , dolasetron , tropisetron ) phenothiazine ( e.g. , prochlorperazine , fluphenazine , perphenazine , thiethylperazine , chlorpromazine ) butyrophenones ( e.g. , haloperidol droperidol ) benzamides ( e.g. , metoclopramide alizapride ) domperidone cannabinoids NK1 receptor antagonist Use , 48 hour prior Treatment Day 1 , benzodiazepine opiate , except single daily dos lorazepam . s. Use follow drug : carbamazepine Fluvoxamine ciprofloxacin dopamine agonist . antiparkinsonian medicinal product medicinal product know increase QTc interval t. Abnormal laboratory value</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>